Fil: Saavedra, Soledad Lorena. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Cátedra de Biotecnología; Argentina.Fil: Ávila, Lucía. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Producción de Biológicos; Argentina.Fil: Giudicessi, Silvana Laura. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Cátedra de Biotecnología; Argentina.Fil: Albericio, Fernando. University of Barcelona. Department of Organic Chemistry; España.Fil: Camperi, Silvia Andrea. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Cátedra de Biotecnología; Argentina.Fil: Cascone, Osvaldo. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Cátedra de Biotecnología; Argentina.Fil: Martinez-Ceron, Maria Camila. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Cátedra de Biotecnología; Argentina.Nowadays, treatment with specific antivenins is considered the only cure for snakebites accidents. However, access to antivenom obstructs the successful implementation of the World Health Organization international guidelines. In the last few years, natural organic compounds, peptides, and proteins with the ability to inhibit snake toxins and obtained from different sources such as plant extracts and animal blood have been proposed as antivenoms. In this work, we will focus on the inhibitors of the main venom toxins, phospholipases A2 and metalloproteinases, and their application as novel antivenoms.